Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Immunogenicity and Efficacy of RH5.2-VLP Malaria Vaccine in Healthy Adults
NCT05978037Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Aug 2023
- Primary completion
- Apr 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of RH5.2-VLP in malaria, sponsored by University of Oxford. Started Aug 2023; status: completed.
02
Drugs
RH5.2-VLP
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05978037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978037.